- Home
- / Ribon Therapeutics
Ribon Therapeutics
Total Funding
$65 M
Ribon Therapeutics Summary
Company Summary
- Overview
- Ribon Therapeutics is pioneering the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells’ fundamental ability to survive under stress
- Type
- Private
- Status
- Active
- Founded
- 2015
- Website
- http://www.ribontx.com/
- Cybersecurity rating
- Sectors
Table of Contents
Key People
Sally Johnson, Chief People Officer
Jodie Morrison, Chair of the Board Of Directors
Laura Brass, Member of the Board
